A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

被引：0
|
作者：
De Tursi, M.
Carella, C.
Ricevuto, E.
Marchetti, P.
Gennari, A.
Orlandini, C.
Frassoldati, A.
Conte, P.
Iacobelli, S.
机构：
[1] Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[2] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy
[3] Univ Pisa, Dept Oncol, I-56100 Pisa, Italy
[4] Univ Modena, Dept Oncol, I-41100 Modena, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [31] Gemzar®(Ci) and epirubicin (E) in patients (pts) with metastatic breast cancer(MBC):: Final results of a phase I dose finding study
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Espie, M
    Kayitalire, L
    Rongier, AM
    Pouillart, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S292 - S292
  • [32] First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+MBC): A Minnie Pearl Cancer Research Network phase II trial.
    Yardley, DA
    Greco, FA
    Porter, LL
    Burris, HA
    Phelps, C
    Webb, C
    Schlabach, L
    Fichtel, LM
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 37S - 37S
  • [33] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Rugo, Hope S.
    Chien, A. Jo
    Franco, Sandra X.
    Stopeck, Alison T.
    Glencer, Alexa
    Lahiri, Soumi
    Arbushites, Michael C.
    Scott, Janet
    Park, John W.
    Hudis, Clifford
    Nulsen, Ben
    Dickler, Maura N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 13 - 20
  • [34] Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results
    Brufsky, A
    Orlando, M
    Fox, K
    Jame, A
    Katherine, T
    Franco, S
    Vincent, H
    Terry, E
    LaTrice, H
    Steven, S
    Allen, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
  • [35] MULTICENTER PHASE-II STUDY OF LOW-DOSE INTRAVESICAL EPIRUBICIN IN THE TREATMENT OF SUPERFICIAL BLADDER-CANCER
    WHELAN, P
    CUMMING, JA
    GARVIE, WHH
    HARGREAVE, TB
    KIRK, D
    NEWLING, DWW
    ROBINSON, MRG
    SMITH, PH
    BRITISH JOURNAL OF UROLOGY, 1991, 67 (06): : 600 - 602
  • [36] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S. Rugo
    A. Jo Chien
    Sandra X. Franco
    Alison T. Stopeck
    Alexa Glencer
    Soumi Lahiri
    Michael C. Arbushites
    Janet Scott
    John W. Park
    Clifford Hudis
    Ben Nulsen
    Maura N. Dickler
    Breast Cancer Research and Treatment, 2012, 134 : 13 - 20
  • [37] Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer:: Results of a multicenter phase II study
    Palmeri, S
    Vaglica, M
    Spada, S
    Filippelli, G
    Farris, A
    Palmeri, L
    Massidda, B
    Misino, A
    Ferraù, F
    Comella, G
    Leonardi, V
    Condemi, G
    Mangiameli, A
    De Cataldis, G
    Macaluso, MC
    Cajozzoo, M
    Iannitto, E
    Danova, M
    ONCOLOGY, 2005, 68 (4-6) : 438 - 445
  • [38] Phase II study with paclitaxel (P) and novantrone (N) as first line treatment in metastatic breast cancer (MBC).
    Fontaine, C
    Neyns, B
    Van Erps, J
    Dewaele, A
    De Grève, J
    ANNALS OF ONCOLOGY, 2000, 11 : 37 - 38
  • [39] Docetaxel versus epirubicin/cyclophosphamide(EC) as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study
    不详
    BREAST, 2005, 14 : S41 - S41
  • [40] Cardiac safety of herceptin (H) in combination with epirubicin (E) plus cyclophosphamide (C): interim results of a phase II study in patients with metastatic breast cancer.
    Lueck, HJHJ
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 286 - 286
12345